Who is sponsoring NCT04778553?

NCT04778553 is sponsored by Essenlix Corporation.

What drugs are being tested in NCT04778553?

Interventions in NCT04778553: iMOST X-1 Hematology Analyzer.

What condition does NCT04778553 study?

NCT04778553 studies Hematologic Tests.

Is NCT04778553 still recruiting?

NCT04778553 is currently completed. Last updated 3 March 2021.

Last reviewed 2021-03-03 · How we verify

NCT04778553

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of the iMOST-X1 Hematology Analyzer - Matrix Study

Completed Last updated 3 March 2021

What this trial tests

trial testing iMOST X-1 Hematology Analyzer in Hematologic Tests in 60 participants. Completed in 21 January 2021.

Timeline

19 October 2020

Primary endpoint
9 December 2020

21 January 2021

Quick facts

Lead sponsor	Essenlix Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	60
Start date	19 October 2020
Primary completion	9 December 2020
Estimated completion	21 January 2021
Sites	1 location across United States

Drugs / interventions tested

iMOST X-1 Hematology Analyzer

Conditions studied

Hematologic Tests — all drugs for Hematologic Tests →

Sponsor

Essenlix Corporation

Who can join

18 and older, any sex, with Hematologic Tests. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a method comparison study for an in vitro diagnostic device. The device is a point of care automated hematology analyzer which measures CBC parameters with a small drop of venous or capillary, e.g., fingerstick blood. The study compared the CBC results from the test device, the Essenlix iMOST X-1 to the predicate laboratory based Horiba Pentra 60C+ analyzer. The CBC parameters were hemoglobin, White Blood Cells (WBC) and the WBC Differential for Granulocytes, Neutrophils, Lymphocytes and Monocytes. The study subjects were patient donors (age 18 and older) attending the hospital clinic from whom Informed Consent had been received.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04778553 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Essenlix Corporation
Last refreshed: 3 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04778553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing